ATE517923T1 - Antikörper gegen amyloid beta mit glykosilierung in der variablen region - Google Patents

Antikörper gegen amyloid beta mit glykosilierung in der variablen region

Info

Publication number
ATE517923T1
ATE517923T1 AT06829502T AT06829502T ATE517923T1 AT E517923 T1 ATE517923 T1 AT E517923T1 AT 06829502 T AT06829502 T AT 06829502T AT 06829502 T AT06829502 T AT 06829502T AT E517923 T1 ATE517923 T1 AT E517923T1
Authority
AT
Austria
Prior art keywords
glycosylation
variable region
antibodies against
amyloid beta
against amyloid
Prior art date
Application number
AT06829502T
Other languages
English (en)
Inventor
Hansruedi Loetscher
Walter Huber
Diana Schuhbauer
Karl Weyer
Manfred Brockhaus
Bernd Bohrmann
Hans Koll
Andreas Schaubmar
Kurt Lang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE517923T1 publication Critical patent/ATE517923T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
AT06829502T 2005-12-12 2006-12-11 Antikörper gegen amyloid beta mit glykosilierung in der variablen region ATE517923T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05027090 2005-12-12
PCT/EP2006/011914 WO2007068429A1 (en) 2005-12-12 2006-12-11 Antibodies against amyloid beta 4 with glycosylated in the variable region

Publications (1)

Publication Number Publication Date
ATE517923T1 true ATE517923T1 (de) 2011-08-15

Family

ID=37745986

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06829502T ATE517923T1 (de) 2005-12-12 2006-12-11 Antikörper gegen amyloid beta mit glykosilierung in der variablen region

Country Status (34)

Country Link
US (2) US8906370B2 (de)
EP (2) EP1960428B1 (de)
JP (1) JP5145241B2 (de)
KR (2) KR20080077132A (de)
CN (2) CN102659943B (de)
AR (1) AR057233A1 (de)
AT (1) ATE517923T1 (de)
AU (1) AU2006326301B2 (de)
BR (1) BRPI0619605B8 (de)
CA (1) CA2632828C (de)
CR (1) CR10000A (de)
CY (1) CY1114783T1 (de)
DK (1) DK1960428T3 (de)
DO (1) DOP2006000278A (de)
EC (1) ECSP088524A (de)
ES (1) ES2368591T3 (de)
HK (2) HK1130066A1 (de)
IL (1) IL191004A (de)
JO (1) JO2824B1 (de)
MA (1) MA30038B1 (de)
MY (1) MY155286A (de)
NO (1) NO346105B1 (de)
NZ (1) NZ568241A (de)
PE (3) PE20100748A1 (de)
PL (1) PL1960428T3 (de)
PT (1) PT1960428E (de)
RS (1) RS52004B (de)
RU (1) RU2438706C2 (de)
SI (1) SI1960428T1 (de)
TW (1) TWI382990B (de)
UA (1) UA99097C2 (de)
UY (1) UY30003A1 (de)
WO (1) WO2007068429A1 (de)
ZA (1) ZA200805038B (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR038568A1 (es) 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
BRPI0619249A2 (pt) 2005-11-30 2011-09-20 Abbott Lab anticorpos anti-globulÈmeros-aß, frações que se ligam a antìgeno destes, hibridomas correspondentes, ácidos nucléicos, vetores, células hospedeiras, métodos de produzir os ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos de usar os ditos anticorpos
IL297746A (en) 2005-11-30 2022-12-01 Abbvie Inc Monoclonal antibodies against amyloid beta protein and uses thereof
UY30003A1 (es) * 2005-12-12 2007-08-31 Hoffmann La Roche Anticuerpos glicosilados en la region variable
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
JP2010512356A (ja) * 2006-12-11 2010-04-22 エフ．ホフマン−ラ ロシュ アーゲー 非経口ａベータ抗体製剤
US20100311767A1 (en) 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
MX2009013340A (es) 2007-06-29 2010-01-18 Hoffmann La Roche Mutante de cadena pesada que lleva a produccion de inmunoglobulina mejorada.
EP3216802B1 (de) 2007-08-20 2020-10-07 Glaxo Group Limited Herstellungsverfahren
PT2238166E (pt) 2007-10-05 2014-02-11 Genentech Inc Utilização do anticorpo anti-amilóide beta em doenças oculares
UA101487C2 (en) * 2007-12-21 2013-04-10 Ф. Хоффманн-Ля Рош Аг Humanized b-ly1 antibody formulation
AU2009242453B2 (en) * 2008-05-02 2014-12-04 Seagen Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
US20140213465A1 (en) * 2011-12-02 2014-07-31 Plaxgen, Inc. Plaque array methods and compositions for forming and detecting plaques
WO2010127069A1 (en) * 2009-04-29 2010-11-04 Schering Corporation Antibody purification
US20130116413A1 (en) * 2009-12-29 2013-05-09 Dr. Reddy's Laboratories, Inc. Purification of proteins
PE20130527A1 (es) 2010-03-03 2013-05-09 Boehringer Ingelheim Int Polipeptidos de union a a-beta biparatopicos
CA2796339C (en) 2010-04-15 2020-03-31 Abbott Laboratories Amyloid-beta binding proteins
RU2607368C2 (ru) 2010-07-30 2017-01-10 Ац Иммуне С.А. Безопасные и функциональные гуманизированные антитела
EP2603524A1 (de) 2010-08-14 2013-06-19 AbbVie Inc. Amyloid-beta-bindende proteine
WO2012142301A2 (en) 2011-04-12 2012-10-18 Quanterix Corporation Methods of determining a treatment protocol for and/or a prognosis of a patients recovery from a brain injury
US9089529B2 (en) * 2011-10-25 2015-07-28 Prothena Therapeutics Limited Antibody formulations and methods
CN104159613B (zh) * 2012-03-08 2016-11-23 霍夫曼-拉罗奇有限公司 Abeta抗体制剂
MX367126B (es) * 2012-08-29 2019-08-06 Hoffmann La Roche Transporte para atravesar la barrera hematoencefálica.
CN102998454A (zh) * 2012-12-11 2013-03-27 华中师范大学 一种检测生物体内邻苯二甲酸二丁酯相对含量的方法
US9587022B2 (en) 2012-12-18 2017-03-07 The Rockefeller University Glycan-modified anti-CD4 antibody with improved HIV-1 neutralizing activity
CN105228650B (zh) 2012-12-18 2018-11-16 美国洛克菲勒大学 用于hiv预防和治疗的聚糖修饰的抗-cd4抗体
AR094780A1 (es) 2013-02-13 2015-08-26 Laboratoire Français Du Fractionnement Et Des Biotechnologies ANTICUERPOS ANTI-TNF-a ALTAMENTE GALACTOSILADOS Y SUS USOS
JP6169885B2 (ja) 2013-05-07 2017-07-26 株式会社日立製作所 精製装置及び精製方法
CA3184564A1 (en) 2013-09-13 2015-03-19 Genentech, Inc. Methods and compositions comprising an anti-il13 antibody and residual hamster phospholipase b-like 2
MX2016002799A (es) 2013-09-13 2016-05-26 Genentech Inc Composiciones y metodos para detectar y cuantificar la proteina en la celula hospedera en las lineas de celulas y productos de polipeptidos recombinantes.
CA2931056C (en) 2013-11-22 2023-02-28 The University Of Tokyo Carrier for use in delivering drug, conjugate, composition comprising same, and method for administrating same
US10562973B2 (en) 2014-04-08 2020-02-18 Prothena Bioscience Limited Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
WO2015165961A1 (en) 2014-04-29 2015-11-05 Affiris Ag Treatment and prevention of alzheimer's disease (ad)
WO2016207240A1 (en) 2015-06-24 2016-12-29 F. Hoffmann-La Roche Ag Anti-transferrin receptor antibodies with tailored affinity
KR102691585B1 (ko) * 2015-08-21 2024-08-05 에프. 호프만-라 로슈 아게 친화성 크로마토그래피에서의 숙주 세포 단백질 감소 방법
JP6657392B2 (ja) 2015-10-02 2020-03-04 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 二重特異性抗ヒトｃｄ２０／ヒトトランスフェリン受容体抗体及び使用方法
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
EP3155958B1 (de) * 2015-10-16 2021-11-17 Roche Diabetes Care GmbH Verfahren zum betreiben eines systems und system
US10759837B2 (en) 2015-11-09 2020-09-01 The University Of British Columbia Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide
WO2017079831A1 (en) 2015-11-09 2017-05-18 The University Of British Columbia N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto
CN108350052A (zh) 2015-11-09 2018-07-31 英属哥伦比亚大学 淀粉样蛋白β中间区域中的表位及其构象选择性抗体
US10792477B2 (en) * 2016-02-08 2020-10-06 Orbusneich Medical Pte. Ltd. Drug eluting balloon
WO2017153848A1 (en) * 2016-03-10 2017-09-14 Genomic Vision Method of curvilinear signal detection and analysis and associated platform
US11326182B2 (en) 2016-04-29 2022-05-10 Voyager Therapeutics, Inc. Compositions for the treatment of disease
TWI798751B (zh) 2016-07-01 2023-04-11 美商美國禮來大藥廠 抗－N3pGlu類澱粉β肽抗體及其用途
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
CN110691592A (zh) * 2017-05-30 2020-01-14 森永乳业株式会社 脑功能改善用组合物
EP3574020B1 (de) 2017-07-18 2024-05-15 The University of British Columbia Antikörper gegen amyloid beta
CN108048477A (zh) * 2017-12-15 2018-05-18 南京理工大学 基于大肠杆菌表达系统的制备多肽的方法
EP3778875A1 (de) 2019-08-14 2021-02-17 MaxiVax SA Immortalisierte myoblast-zellinien und verwendungen davon
KR20230039734A (ko) 2020-07-23 2023-03-21 오타이르 프로테나 리미티드 항-Aβ 항체
CA3200954A1 (en) 2020-11-16 2022-05-19 F. Hoffmann-La Roche Ag Fab high mannose glycoforms
TW202300517A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
WO2022251048A1 (en) 2021-05-24 2022-12-01 Eli Lilly And Company Anti-amyloid beta antibodies and uses thereof
CN114591429B (zh) * 2022-05-07 2022-08-09 北京第一生物化学药业有限公司 结合β-淀粉样蛋白的抗体及其用途
WO2024157085A1 (en) 2023-01-26 2024-08-02 Othair Prothena Limited Methods of treating neurological disorders with anti-abeta antibodies
CN117783359A (zh) * 2023-12-28 2024-03-29 中国计量科学研究院 一种基于串联质谱的转基因蛋白多靶同检方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666829A (en) 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5811310A (en) 1986-09-30 1998-09-22 Albert Einstein College Of Medicine Of Yeshiva Univ. The Alz-50 monoclonal antibody and diagnostic assay for alzheimer's disease
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
CA1339014C (en) 1987-10-08 1997-03-25 Ronald E. Majocha Antibodies to a4 amyloid peptide
JP2780507B2 (ja) 1991-03-29 1998-07-30 松下電器産業株式会社 内燃機関用フィルタ再生装置
US5750349A (en) 1993-01-25 1998-05-12 Takeda Chemical Industries Ltd. Antibodies to β-amyloids or their derivatives and use thereof
US5955317A (en) 1993-01-25 1999-09-21 Takeda Chemical Industries, Ltd. Antibodies to β-amyloids or their derivatives and use thereof
US5443953A (en) * 1993-12-08 1995-08-22 Immunomedics, Inc. Preparation and use of immunoconjugates
GB9416007D0 (en) * 1994-08-08 1994-09-28 Erba Carlo Spa Anthracyclinone derivatives
US5688651A (en) 1994-12-16 1997-11-18 Ramot University Authority For Applied Research And Development Ltd. Prevention of protein aggregation
EP0838033A1 (de) * 1995-06-06 1998-04-29 Stemcell Therapeutics L.L.C. GLYCOPROTEIN gp105, DAS AUF DER OBERFLÄCHE DER HEMATOPOIETISCHEN STAMMZELLEN BL3 ZU FINDEN IST
PT859841E (pt) 1995-08-18 2002-11-29 Morphosys Ag Bibliotecas de proteinas/ (poli) peptidos
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
CA2362834C (en) * 1999-03-04 2005-12-06 Praecis Pharmaceuticals Incorporated Modulators of beta-amyloid peptide aggregation comprising d-amino acids
AU780474B2 (en) 1999-06-16 2005-03-24 Boston Biomedical Research Institute Incorporated Immunological control of beta-amyloid levels in vivo
AU6722300A (en) 1999-08-31 2001-03-26 Ramot University Authority For Applied Research And Industrial Development Ltd. Peptides and substances, methods and devices using same for diagnosing and treating neurodegenerative disorders
JP2004500354A (ja) 1999-11-29 2004-01-08 ニューロケム　インコーポレーティッド 全ｄ体ペプチドを含む、アルツハイマー病およびアミロイド関連疾患の予防および処置のためのワクチン
US20020094335A1 (en) 1999-11-29 2002-07-18 Robert Chalifour Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
EP1125905A1 (de) 2000-02-16 2001-08-22 Pepscan Systems B.V. Synthese von Segmenten
CZ306683B6 (cs) 2000-02-24 2017-05-03 Washington University Léčivo pro prevenci nebo léčení preklinické nebo klinické Alzheimerovy nemoci
CA2313828A1 (en) 2000-08-01 2002-02-01 Institut De Recherches Cliniques De Montreal/Ircm Post-translational processing of .beta.-secretase (bace): the pro-and transmembrane/cytosolic domains affect its cellular activity and amyloid a.beta. production
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
JP2005501220A (ja) 2000-12-19 2005-01-13 パラチン テクノロジーズ インク． ペプチドおよび蛋白質の標的特異的折りたたみ部位の識別
EP1385545B1 (de) 2001-04-30 2009-01-07 Eli Lilly And Company HUMANISIERTE ANTIKÖRPER DIE DAS BETA-AMYLOID PEPTID ERKENNEN& x9;
ATE409047T1 (de) 2001-04-30 2008-10-15 Lilly Co Eli Humanisierte antikörper
CA2451998A1 (en) 2001-08-17 2003-02-27 Eli Lilly And Company Anti-a.beta. antibodies
EP1944040B1 (de) * 2001-08-17 2012-08-01 Washington University Assay-Verfahren für Alzheimer
AR038568A1 (es) * 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
KR20050071564A (ko) 2002-10-09 2005-07-07 리나트 뉴로사이언스 코퍼레이션 아밀로이드 베타 펩티드에 대한 항체를 사용하여알츠하이머병을 치료하는 방법 및 그의 조성물
DE10303974A1 (de) * 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
UY30003A1 (es) * 2005-12-12 2007-08-31 Hoffmann La Roche Anticuerpos glicosilados en la region variable
JP2010512356A (ja) * 2006-12-11 2010-04-22 エフ．ホフマン−ラ ロシュ アーゲー 非経口ａベータ抗体製剤

Also Published As

Publication number Publication date
HK1176075A1 (en) 2013-07-19
CY1114783T1 (el) 2016-12-14
UA99097C2 (ru) 2012-07-25
JP2009520691A (ja) 2009-05-28
ZA200805038B (en) 2009-06-24
JP5145241B2 (ja) 2013-02-13
BRPI0619605A8 (pt) 2019-01-15
CA2632828A1 (en) 2007-06-21
KR101401159B1 (ko) 2014-05-29
US20150165022A1 (en) 2015-06-18
MA30038B1 (fr) 2008-12-01
EP2377886A1 (de) 2011-10-19
WO2007068429A1 (en) 2007-06-21
NO20082874L (no) 2008-08-28
JO2824B1 (en) 2014-09-15
CN102659943A (zh) 2012-09-12
AR057233A1 (es) 2007-11-21
CN101351476A (zh) 2009-01-21
US20090252724A1 (en) 2009-10-08
TW200736273A (en) 2007-10-01
NZ568241A (en) 2011-08-26
TWI382990B (zh) 2013-01-21
ECSP088524A (es) 2008-07-30
AU2006326301B2 (en) 2011-04-21
PE20071002A1 (es) 2007-11-19
PL1960428T3 (pl) 2012-02-29
CN101351476B (zh) 2013-04-03
ES2368591T3 (es) 2011-11-18
RS52004B (en) 2012-04-30
UY30003A1 (es) 2007-08-31
PE20100748A1 (es) 2010-11-12
IL191004A (en) 2013-08-29
US8906370B2 (en) 2014-12-09
EP1960428B1 (de) 2011-07-27
BRPI0619605A2 (pt) 2011-10-11
HK1130066A1 (en) 2009-12-18
CN102659943B (zh) 2015-07-01
CA2632828C (en) 2012-07-10
US9272031B2 (en) 2016-03-01
RU2438706C2 (ru) 2012-01-10
DOP2006000278A (es) 2007-07-15
KR20080077132A (ko) 2008-08-21
MY155286A (en) 2015-09-30
KR20120089483A (ko) 2012-08-10
AU2006326301A1 (en) 2007-06-21
CR10000A (es) 2008-07-29
BRPI0619605B1 (pt) 2019-08-13
PE20100684A1 (es) 2010-10-04
SI1960428T1 (sl) 2011-10-28
RU2008128138A (ru) 2010-01-20
PT1960428E (pt) 2011-10-07
NO346105B1 (no) 2022-02-21
EP1960428A1 (de) 2008-08-27
DK1960428T3 (da) 2011-08-22
BRPI0619605B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
ATE517923T1 (de) Antikörper gegen amyloid beta mit glykosilierung in der variablen region
ATE485941T1 (de) Werkstoffverbund mit explosionsgeschweisstem zwischenstück
NL1031106A1 (nl) Verstrooiende structuur met UV-absorberende eigenschappen.
DE602005011683D1 (de) Turbolader mit variabler düse
DK1970446T3 (da) Nukleær reprogrammeringsfaktor
DE602006014125D1 (de) Banksitz mit beweglichen polstern
CR20130381A (es) Formas farmacéuticas con propiedades farmacocinéticas mejoradas
DE602006006428D1 (de) Material mit trennbarer struktur
DE502006001085D1 (de) Messwertaufnehmer mit zumindest einem saw-element
DE502006006105D1 (de) Matrize mit kleinen näpfchenartigen vertiefungen
DE602006018649D1 (de) Flugzeug mit modularer struktur
DE502005007606D1 (de) Bauteil mit rohrförmigem Abschnitt
ATE399089T1 (de) Verbundbauteil mit strukturiertem wolframteil
ATE410372T1 (de) Wafervial mit internen zwischenlagen
DE502005000284D1 (de) Fahrzeug mit offenem Aufbau
FIU20050316U0 (fi) Työpisteasema ja laitteisto työpisteaseman yhteydessä
FI20050068A0 (fi) Linssirakenne
NO20052429D0 (no) Konstrastmidler
FI20045499A0 (fi) Järjestely oskillointilaitteessa
ITFR20050003A1 (it) Traliccio "conte" muniti di due piattine con tondino distanziatore
FI20040452A0 (fi) Rakenne-elementti
FI20055146A0 (fi) Virtauksenjakaja
ITFR20050004U1 (it) Traliccio "conte" muniti di due piattinecon tondino distanziatore
DE602005007353D1 (de) Ventileinheit und Einspritzventil mit derselben
FIU20040059U0 (fi) Sisustuselementtirakenne

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1960428

Country of ref document: EP